Abstract:Purpose: HM-3, an RGD-modified endostatin-derived polypeptide, is a potent angiogenesis inhibitor synthesized in our laboratory. This study investigated the HM-3 pharmacokinetics of intravitreally administered in mice eyes as an anti-angiogenesis drug for age-related macular degeneration.Materials and methods: A total of 288 C57BL/6J mice were evaluated and divided into four groups. Each mouse in different groups received single bilateral intravitreal injection with HM-3. The concentrations of HM-3 in choroid/sclera, retina and serum were determined by indirect competitive enzyme-linked immunosorbent assay.Results: After intravitreal administration of doses of 0, 10, 20 and 40 mu g/eye HM-3, the observed maximum concentration (C-max) was 12.98 +/- 1.42, 27.87 +/- 3.64 and 55.96 +/- 11.94 ng/mg, respectively; and the total area under the curve (AUC(tot)) was 739.23 +/- 190.32, 1171.74 +/- 528.75 and 1777.71 +/- 511.64 h ng/mg; the elimination half-life (T-1/2) in retina was 104.85 +/- 36.90, 107.42 +/- 35.25 and 101.12 +/- 15.82 h; the mean residence time (MRT) was 172.46 +/- 63.80, 164.70 +/- 52.72 and 181.32 +/- 26.01 h, respectively. In choroid/sclera, the C-max was 5.29 +/- 0.34, 6.29 +/- 1.87 and 8.14 +/- 0.71 ng/mg, respectively; AUC(tot) was 579.03 +/- 56.50, 762.20 +/- 201.09 and 720.91 +/- 243.87 h ng/mg; T-1/2 was 54.04 +/- 25.99, 59.33 +/- 24.46 and 47.10 +/- 10.00 h, respectively; MRT was 139.98 +/- 23.93, 155.43 +/- 17.81 and 136.45 +/- 18.17 h, respectively. But in serum, the C-max was 482.00 +/- 38.97, 493.94 +/- 97.64 and 1033.10 +/- 276.33 ng/ml, respectively; AUC(tot) was 21128.55 +/- 4683.68, 53444.57 +/- 16963.99 and 53164.84 +/- 1535.06 h ng/ml; T-1/2 was 48.39 +/- 14.89, 47.96 +/- 12.97 and 49.98 +/- 30.07 h, respectively; MRT was 108.6 +/- 47.17, 159.76 +/- 18.82 and 125.33 +/- 21.41 h, respectively.Conclusions: The pharmacokinetic profiles of intravitreal administration HM-3 provide the basis for the development of reasonable dosing regimens of clinical choroidal neovascularization (CNV) treatment. However, the vitreous and blood retinal barrier might be barriers to drug distribution and diffusion. In addition, fluid flow for the anterior transport and choroidal blood circulation might play important roles for multiple peaking. Carrying out the research into pharmacokinetics of HM-3 provides the information for laying down drug delivery scheme in mice model of CNV.

HM-3 Inhibiting Angiogenesis in Vitro

Antitumor effects of peptide HM-3 against non-small cell lung cancer xenografts in nude mice

[Corrigendum] in Vitro and in Vivo Activities of an Antitumor Peptide HM-3: A Special Dose-Efficacy Relationship on an HCT‑116 Xenograft Model in Nude Mice.

RGD-modified angiogenesis inhibitor HM-3 dose: dual function during cancer treatment.

HM-3-HSA exhibits potent anti-angiogenesis and antitumor activity in hepatocellular carcinoma

FP3: a Novel VEGF Blocker with Antiangiogenic Effects in Vitro and Antitumour Effects in Vivo

The experimental study of ginsenoside Rg3 on inhibiting angiogenesis

Effects of Three Compounds Extracted from Tripterygium Wilfordii Hook on Angiogenesis in Chick Chorioallantoic Membrane

Inhibition Of Angiogenesis By A Novel Neutralizing Antibody Targeting Human Vegfr-3

Experimental Study on Antiangiogenesis of Monomer TW3 from Tripterygium Wilfordii

The Inhibition of Ursolic Acid on Angiogenesis in Vitro and in Vivo

FP3: a Novel VEGF Blocker with Anti-Angiogenic and Anti-Tumor Effects.

Experimental study of extract of fungi of huaier on angiogenesis in vitro

Studies of poly(ethylene glycol) modification of HM-3 polypeptides.

The Inhibition of Angiogenesis by Shenmai Combined with Hydroxycamptothecin

An Integrin Αvβ3 Antagonistic Modified Peptide Inhibits Tumor Growth Through Inhibition of the ERK and AKT Signaling Pathways.

In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by Different Polyethylene Glycols (PEG)

The Anti-Angiogenic and Anti-Proliferative Activity of Methyl Hydroxychalcone

Pharmacokinetics of HM-3 after Intravitreal Administration in Mice

PEGylated HM-3 presents anti-rheumatic bioactivity by inhibiting angiogenesis and inflammation

Newly synthesized quinazolinone HMJ-38 suppresses angiogenetic responses and triggers human umbilical vein endothelial cell apoptosis through p53-modulated Fas/death receptor signaling.